Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p<0.0001 / p=0.0035)
- Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels
- Detailed results presented today at the Seventeenth European Meeting on Hypertension in Milan, Italy

SCHLIEREN (Zurich), Switzerland and MILAN, Italy, June 17, 2007 - Cytos Biotechnology AG (SWX:CYTN) presented today new clinical data on its hypertension vaccine CYT006-AngQb at the Seventeenth European Meeting on Hypertension in Milan, Italy. The vaccine candidate was tested in a placebocontrolled, double-blind phase IIa clinical trial in 72 patients with mild to moderate hypertension.

On January 26, 2007, Cytos Biotechnology reported top-line data from this study, which showed that the 300 ?g dose of the vaccine was safe, very well tolerated and efficacious in lowering day-time ambulatory blood pressure. The new data presented today show a particularly strong efficacy of the vaccine in early morning hours, a critical time period when serious cardiovascular events frequently occur. The graph below shows the mean ambulatory blood pressure during the 24-hour measurement period 14 weeks after the first injection of the vaccine or of placebo. The early morning rise of blood pressure starting at 5 am was significantly suppressed by the vaccine, leading at 8 am to a change from baseline of the blood pressure of - 25 / - 13 mm Hg compared to placebo (SBP / DBP, p<0.0001 / p=0.0035).


*SEE ATTACHMENT FOR FIGURE*

The strong suppression of the early morning rise of blood pressure was associated with an exceptionally low increase in plasma renin concentration (PRC) from a mean renin concentration of 5.1 pg/ml at baseline to 6.3 pg/ml at week 14 (p=0.02). Inhibition of the renin-angiotensin system by small molecule drugs is known to induce a reactive rise of the plasma renin concentrati
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:3/30/2015)... ATLANTA , March 30, 2015  Edelberg ... the first of its kind, real-time medical coding ... the patient, physician, scribe and medical coder at ... lengthy collaboration initiative with ScribeAmerica, EA has successfully ... method for real-time interaction between scribe and medical ...
(Date:3/30/2015)... Calif. , March 30, 2015 ... that it has initiated a multi-dose Phase 1 ... the lead molecule in DURECT,s Epigenomic Regulator Program.  ... (NCE) that may have broad applicability in metabolic ... and nonalcoholic steatohepatitis (NASH).  It may also play ...
(Date:3/30/2015)... March 30, 2015   GlassesUSA , the online retailer ... $12.5 million in new financing led by Viola Private ... will further GlassesUSA,s aggressive business growth and accelerate their expansion ... online eyewear, both B2C and B2B. GlassesUSA was ... Eldad Rothman , and CTO Roy Yamner . ...
Breaking Medicine Technology:Edelberg & Associates and ScribeAmerica Partner to Launch Healthcare Industry's First Ever Real-time Medical Coding Solution 2Edelberg & Associates and ScribeAmerica Partner to Launch Healthcare Industry's First Ever Real-time Medical Coding Solution 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3
... 16, 2010 New results from an observational ... American Heart Association (AHA) Scientific Sessions annual meeting ... to coronary artery bypass graft surgery (CABG) had ... treated with Plavix® (clopidogrel) (2.3 percent versus 8.7 ...
... Decision Resources, one of the world,s leading research ... that, owing to the launch of several novel agents, ... than triple from approximately $2 billion in 2009 to ... France, Germany, Italy, Spain, the United Kingdom and Japan. ...
Cached Medicine Technology:Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 2Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 3Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 4Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 5Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 6The Hepatitis C Virus Drug Market Will Nearly Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments 2The Hepatitis C Virus Drug Market Will Nearly Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments 3
(Date:3/30/2015)... 30, 2015 Wright & Schulte LLC, ... notes that the number of Syngenta corn lawsuits ... in U.S. District Court, District of Kansas, have risen ... "According to an update released by the U.S. Judicial ... least 493 Syngenta lawsuits are now consolidated in the ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 A new ... in California Superior Court on behalf of a child ... defect after his mother was prescribed the anti-nausea medication ... March 6th filing in Alameda Superior Court, the baby’s ... vomiting that she experienced in the early months of ...
(Date:3/30/2015)... 30, 2015 On March 11, 2015, Elle ... Away Fat,” details six new treatment options for dealing with ... one is a topical product. The other three technologies use ... Liposonix ) or freezing cold ( CoolSculpting ) to kill ... now available to us to permanently remove unwanted fat," says ...
(Date:3/30/2015)... In a recent report published by ... Christie is championing effective drug and alcohol treatment for ... to recover funds to stabilize the addiction treatment programs, ... of drug and alcohol addiction. Harbor Village Detox is ... substance use disorders in New Jersey, in hopes to ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 This ... software market over the forecast period of 2014 ... at a CAGR of 6.5% from 2014 to ... , In this report, the global pharmacovigilance and ... many segments on the basis of functionality, namely, ...
Breaking Medicine News(10 mins):Health News:Syngenta Corn Lawsuit Claims Continue To Be Filed By Non GMO Corn Farmers Reports Wright & Schulte LLC 2Health News:Syngenta Corn Lawsuit Claims Continue To Be Filed By Non GMO Corn Farmers Reports Wright & Schulte LLC 3Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 2Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 3Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 4Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4
... and cursed: the Stanev gypsy family parted with their three ... European Union, rescued this week from years of abuse . ... our bears, our kids?" a tearful Velichka Staneva, 58, cried ... son, Veselin, led out his 19-year-old male bear Misho and ...
... Tens of thousands Saturday staged the Gay Pride parade ... to grant homosexual couples legal status and override Vatican ... which included transvestites and lawmakers, marched under a baking ... of Saint John Lateran, the official ecclesiastical seat of ...
... been together for 18 years, and rocker Jon Bon Jovi insists ... another woman. ,Jovi, who has seen the collapse ... Richie Sambora, insists that his wife is really something special to ... that he's 'had his lapses'. ,"I wouldn't trade her in ...
... Jessica Alba prefers a hot one-night stand to being in ... magazine, admitted that she doesn't think that one-night stands or ... that she has indulged in several one-night trysts. ,"I ... with different people. I don't think a girl's a sl*t ...
... England's top footballers woke up as married men Sunday ... ultimate WAG wedding weekend. ,The off-field antics ... of England's footballers were as much the focus as ... World Cup. And there was an almighty fixture pile-up ...
... expensive technique for mutating those large, non-gene stretches of DNA. ... human genetic blueprint , yet diseases can result not only ... controls genes. ,Diseases are known to occur as ... method allows us to evaluate what these sequences do, says ...
Cached Medicine News:Health News:Europe's Last Dancing Bears Sheltered After Years of Abuse 2Health News:Gay Pride Attracts Tens of Thousands in Rome 2Health News:WAG Wedding Extravaganza for England Footballers 2Health News:Genome Annotation by Mutation 2Health News:Genome Annotation by Mutation 3Health News:Genome Annotation by Mutation 4Health News:Genome Annotation by Mutation 5
Girard angled tying forceps made of titanium has angled 45 shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 102 mm....
McPherson curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 85 mm....
Tying forceps with flat serrated handle 88 mm, made of titanium, angled 30 with 4.5 mm tying platform....
Round handle colibri tying forceps with 5 mm titanium coated platforms. Length 100 mm....
Medicine Products: